



UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

E. Raspe *et al.* : Examiner: S. Chunduru

Serial No.: 09/646,924 : Group Art Unit: 1656

Filed: September 25, 2000 :

For: **USE OF ROR RECEPTORS FOR SCREENING SUBSTANCES USEFUL
FOR THE TREATMENT OF ATHEROSCLEROSIS**

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

I hereby certify that this correspondence is being deposited with the U.S. Postal Services as First Class Mail in an envelope addressed to:
Assistant Commissioner For Patents,
Washington, D.C. 20231 on: 4/1/02
Name: Ja Ann P. Hughes
Signature: Ja Ann P. Hughes
Date: 4/1/02

Sir:

In response to the Office Action of November 1, 2001, please amend the above-identified application as follows:

IN THE CLAIMS:

Please amend claims 1, 3, 4, 7, 8, 16 and 22 as follows:

1. (Twice Amended) A method of screening a substance for usefulness in the treatment of a lipid metabolism dysfunction comprising contacting said substance with a ROR receptor, or a response element thereof involved in the regulation of the apo C-III gene, and measuring the level of apo C-III gene expression.

3. (Twice Amended) A method of screening a substance for usefulness in the treatment of a lipid metabolism dysfunction, comprising contacting said substance with (a) a receptor of the ROR family involved in the regulation of the expression of the apo C-III gene, (b) a response element of the ROR receptor, or (c) a nuclear factor which functionally couples ROR to a RNA polymerase complex, and then measuring:

#12/Amndt
4/19
RECEIVED
APR 17 2002
TECH CENTER 1600/2900